PropertyValue
?:abstract
  • At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped positive-sense RNA virus, was identified for the first time in Wuhan, a city in the Chinese province of Hubei, as the cause of a new pathology which was later named coronavirus disease of 2019 (COVID-19).1 SARS-CoV2 belongs to the family Coronaviridae and shares 79% nucleotide sequence identity with SARS-CoV and 96% with bat-coronavirus RatG13.1,2 The most frequent symptoms of COVID-19 are cough, fever and weakness but it can lead to severe and potentially fatal forms of pneumonia.
is ?:annotates of
?:creator
?:journal
  • Basic_clin._pharmacol._toxicol
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 In Vitro
?:type
?:who_covidence_id
  • #965811
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/1pb8cv4w>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/1pb8cv4w>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all